Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.81 |
| ▸ | SOAT1 | P35610 | 11/20 | 0.81 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399582 | 1.00 | DGAT1 (0.81) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL12809187 | 0.91 | DGAT1 (0.67) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL12809359 | 0.91 | DGAT1 (0.67) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL14336237 | 0.91 | DGAT1 (0.67) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL2247610 | 0.90 | DGAT1 (1.00) | DGAT1SOAT1DGAT2 | |
| SCHEMBL2246590 | 0.90 | DGAT1 (1.00) | DGAT1SOAT1DGAT2 | |
| SCHEMBL2246586 | 0.90 | DGAT1 (1.00) | DGAT1SOAT1DGAT2 | |
| SCHEMBL1399522 | 0.89 | DGAT1 (0.73) | DGAT1SOAT1DGAT2MAPTNPC1 | |
| SCHEMBL1399729 | 0.88 | DGAT1 (0.88) | DGAT1SOAT1DGAT2 | |
| SCHEMBL3540296 | 0.85 | DGAT1 (1.00) | DGAT1SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | DGAT1 1/4885SOAT1 5/4885DGAT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.